Categories Uncategorized

Eating Early Has No Impact on Weight-Loss Efforts

According to ongoing research that was presented during a recent virtual meeting at the American Heart Association Scientific Session, it was discovered that limiting meals to early in the day didn’t affect the weight of overweight adults who have diabetes or prediabetes.

Associate professor of epidemiology, nursing and medicine at Johns Hopkins, Nisa M. Maruthur, the study’s author, stated that researchers had questioned the possibility of whether the time that an individual ate during the day affected how their body stored and used energy. Prior studies had not controlled the number of calories people consumed. It had therefore not been clear whether individuals who ate earlier in the day ate fewer calories. To remedy this, their study changed the time during the day when an individual ate.

During their three-month study, Maruthur and her colleagues observed 41 adults who were overweight. A majority of the participants were black women with an average age of 59 years who had diabetes or prediabetes. They made up 90% of the participants in the study. During the study, twenty participants ate in a 12-hour window at their usual eating times, ingesting half of their daily calories after 5 p.m. for the entire duration of the study. The remaining 21 participants followed an eating pattern that was time restricted.

This limited their eating to specific hours of the day. They consumed 80% of their daily calories before 1 p.m. with all 41 participants eating the same healthy, preprepared meals that were provided for them in the study. At the beginning of the study, the blood pressure and weight for each participant was measured. This was then measured four weeks and eight weeks after the study commenced, as well as when the study ended.

The researchers’ analysis discovered that individuals in both groups had decreased blood pressure and had lost weight, regardless of what they consumed. Maruthur explained that initially, they thought the group that had a time-restricted eating pattern would lose more weight. However, they noted no differences in weight loss in either groups.

Currently, the researchers are gathering more detailed information on blood pressure documented over a 24-hour period. They will then compile this information with the findings of a study that centered on the effects of time-restricted eating on insulin, blood sugar and other hormones. Maruthur added that, when combined, the findings from both studies would help the researchers better understand the impact time-restricted feeding had on cardio-metabolic health.

Many companies are out there contributing to improving human health in different ways. One of those dedicated companies that you should pay attention to is AzurRx BioPharma Inc. (NASDAQ: AZRX). AzurRx is focused on developing novel treatments for diseases that affect the gastrointestinal tract.

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035

The global market for brain tumor treatments is experiencing significant transformation powered by advances in…

1 day ago

New Blood Test Shows Potential in Revolutionizing Early Parkinson’s Detection

A team of researchers has developed a “cost-effective” and simple blood test with the potential…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Is ‘One to Watch’

Nutriband’s AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible…

3 days ago

Nutriband Inc. (NASDAQ: NTRB) Leading the Way in Transformative Partnerships Formed in Growing Pharma Sector

Strategic partnerships embrace opportunities to foster innovation, streamline processes and ultimately improve the lives of…

4 days ago

Adageis Helps Medical Providers Track and Build Revenue Through Efficient Application of Value-Based Care

Adageis provides clinics and medical groups with AI-powered tools to track financial outcomes tied to…

1 week ago

Blocking an Enzyme in Melanoma Patients Could Overcome Resistance to Immunotherapy

Approximately 65% of patients diagnosed with melanoma are unresponsive to immunotherapy. New research suggests that…

1 week ago